Background: First-line (1L) therapy with pembrolizumab in patients with metastatic NSCLC without targetable aberrations and programmed death ligand 1 (PD-L1) tumor proportion score (TPS) 50% significantly improved the primary endpoint of PFS, and OS (secondary endpoint) compared to chemotherapy in the KEYNOTE-024 study. In KEYNOTE-042 (NCT02220894), we evaluated pembrolizumab vs chemotherapy at the lower PD-L1 TPS of 1%. Method: Eligible patients were randomized 1:1 to 35 cycles of pembrolizumab 200 mg Q3W or investigator's choice of 6 cycles of paclitaxel + carboplatin or pemetrexed + carboplatin with optional pemetrexed maintenance (nonsquamous only). Randomization was stratified by region (east Asia vs non-east Asia), ECOG PS (0 vs 1), histology (squamous vs nonsquamous), and TPS (50% vs 1-49%). Primary endpoints were OS in patients with TPS 50%, 20%, and 1%. OS differences were assessed sequentially using the stratified log-rank test. Efficacy boundaries at the prespecified second interim analysis were one-sided P ¼ 0.0122, 0.01198, and 0.01238, respectively. Results: Overall, 1274 patients were randomized: 637 to each arm. 599 patients (47.0%) had TPS 50%, 818 (64.2%) had TPS 20%. After a median follow-up of 12.8-months, 13.7% were still on pembrolizumab and 4.9% were receiving pemetrexed maintenance. Pembrolizumab significantly improved OS in patients with TPS 50% (HR 0.69), TPS 20% (HR 0.77), and TPS 1% (HR 0.81) (Table) . Grade 3-5 drug-related AEs were less frequent with pembrolizumab (17.8% vs 41.0%). The external DMC recommended continuing the trial to evaluate PFS (secondary endpoint). Conclusion: KEYNOTE-042 is the first study with a primary endpoint of OS to demonstrate superiority of pembrolizumab over platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic NSCLC without sensitizing EGFR or ALK abberations and a PD-L1 TPS 1%. These data confirm and potentially extend the role of pembrolizumab monotherapy as a standard 1L treatment for PD-L1-expressing locally advanced or metastatic NSCLC.
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